tiprankstipranks
The Fly

Tarsus Pharmaceuticals price target lowered to $60 from $62 at Barclays

Tarsus Pharmaceuticals price target lowered to $60 from $62 at Barclays

Barclays lowered the firm’s price target on Tarsus Pharmaceuticals (TARS) to $60 from $62 and keeps an Overweight rating on the shares following the Q4 report. The firm says Xdemvy 2025 sales growth will vary by quarter.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com